These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24146025)

  • 1. SGOL1 variant B induces abnormal mitosis and resistance to taxane in non-small cell lung cancers.
    Matsuura S; Kahyo T; Shinmura K; Iwaizumi M; Yamada H; Funai K; Kobayashi J; Tanahashi M; Niwa H; Ogawa H; Takahashi T; Inui N; Suda T; Chida K; Watanabe Y; Sugimura H
    Sci Rep; 2013 Oct; 3():3012. PubMed ID: 24146025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel tumor-derived SGOL1 variant causes abnormal mitosis and unstable chromatid cohesion.
    Kahyo T; Iwaizumi M; Shinmura K; Matsuura S; Nakamura T; Watanabe Y; Yamada H; Sugimura H
    Oncogene; 2011 Nov; 30(44):4453-63. PubMed ID: 21532624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
    Dalvi MP; Wang L; Zhong R; Kollipara RK; Park H; Bayo J; Yenerall P; Zhou Y; Timmons BC; Rodriguez-Canales J; Behrens C; Mino B; Villalobos P; Parra ER; Suraokar M; Pataer A; Swisher SG; Kalhor N; Bhanu NV; Garcia BA; Heymach JV; Coombes K; Xie Y; Girard L; Gazdar AF; Kittler R; Wistuba II; Minna JD; Martinez ED
    Cell Rep; 2017 May; 19(8):1669-1684. PubMed ID: 28538184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-337-3p and its targets STAT3 and RAP1A modulate taxane sensitivity in non-small cell lung cancers.
    Du L; Subauste MC; DeSevo C; Zhao Z; Baker M; Borkowski R; Schageman JJ; Greer R; Yang CR; Suraokar M; Wistuba II; Gazdar AF; Minna JD; Pertsemlidis A
    PLoS One; 2012; 7(6):e39167. PubMed ID: 22723956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase.
    Giovinazzi S; Morozov VM; Summers MK; Reinhold WC; Ishov AM
    Cell Death Differ; 2013 May; 20(5):721-31. PubMed ID: 23348568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice.
    Chung CT; Yeh KC; Lee CH; Chen YY; Ho PJ; Chang KY; Chen CH; Lai YK; Chen CT
    Pharmacol Res; 2020 Nov; 161():105183. PubMed ID: 32896579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
    Lai GGY; Lim TH; Lim J; Liew PJR; Kwang XL; Nahar R; Aung ZW; Takano A; Lee YY; Lau DPX; Tan GS; Tan SH; Tan WL; Ang MK; Toh CK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Yuan J; Lim TKH; Lim AST; Hillmer AM; Lim WT; Iyer NG; Tam WL; Zhai W; Tan EH; Tan DSW
    J Clin Oncol; 2019 Apr; 37(11):876-884. PubMed ID: 30676858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells.
    Filosto S; Baston DS; Chung S; Becker CR; Goldkorn T
    Mol Cancer Ther; 2013 Aug; 12(8):1579-90. PubMed ID: 23686837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
    Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
    Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
    Pillai RN; Brodie SA; Sica GL; Shaojin Y; Li G; Nickleach DC; Yuan L; Varma VA; Bonta D; Herman JG; Brock MV; Ribeiro MJ; Ramalingam SS; Owonikoko TK; Khuri FR; Brandes JC
    Clin Cancer Res; 2013 Mar; 19(6):1603-11. PubMed ID: 23386692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.
    Salido M; Pijuan L; Martínez-Avilés L; Galván AB; Cañadas I; Rovira A; Zanui M; Martínez A; Longarón R; Sole F; Serrano S; Bellosillo B; Wynes MW; Albanell J; Hirsch FR; Arriola E
    J Thorac Oncol; 2011 Jan; 6(1):21-7. PubMed ID: 21107285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.
    Cappuzzo F; Jänne PA; Skokan M; Finocchiaro G; Rossi E; Ligorio C; Zucali PA; Terracciano L; Toschi L; Roncalli M; Destro A; Incarbone M; Alloisio M; Santoro A; Varella-Garcia M
    Ann Oncol; 2009 Feb; 20(2):298-304. PubMed ID: 18836087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target.
    Yu JJ; Zhou DD; Yang XX; Cui B; Tan FW; Wang J; Li K; Shang S; Zhang C; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Huang B; Hua F; Hu ZW
    Nat Commun; 2020 Jul; 11(1):3660. PubMed ID: 32694521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
    Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
    Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues.
    Liang H; Zhang J; Shao C; Zhao L; Xu W; Sutherland LC; Wang K
    J Exp Clin Cancer Res; 2012 Apr; 31(1):36. PubMed ID: 22537942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
    Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
    Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.
    Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Segura-Carretero A; Joven J; Martin-Castillo B; Barrajón-Catalán E; Micol V; Bosch-Barrera J; Menendez JA
    Cell Cycle; 2013 Nov; 12(21):3390-404. PubMed ID: 24047698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of NEK2 promotes lung cancer progression and drug resistance and is regulated by mutant EGFR.
    Chen C; Peng S; Li P; Ma L; Gan X
    Mol Cell Biochem; 2020 Dec; 475(1-2):15-25. PubMed ID: 32761510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secreted frizzled related protein 1 modulates taxane resistance of human lung adenocarcinoma.
    Ren J; Wang R; Song H; Huang G; Chen L
    Mol Med; 2014 Apr; 20(1):164-78. PubMed ID: 24643460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.